Abstract
IntroductionA significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present with persistent, disabling fatigue similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-viral fatigue syndromes. There remains no clear pharmacological therapy for patients with this subtype of PCC, which can be referred to as post-COVID fatigue syndrome (PCFS). A low dose of the opioid antagonist naltrexone (ie, low-dose naltrexone (LDN)) has emerged as an off-label treatment for treating fatigue and other symptoms in PCC. However, only small, non-controlled studies have assessed LDN in PCC, so randomised trials are urgently required.Methods and analysisA prospective, randomised, double-blind, parallel arm, placebo-controlled phase II trial will be performed to assess the efficacy of LDN for improving fatigue in PCFS. The trial will be decentralised and open to eligible individuals throughout the Canadian province of British Columbia (BC). Participants will be recruited through the province-wide Post-COVID-19 Interdisciplinary Clinical Care Network (PC-ICCN) and research volunteer platform (REACH BC). Eligible participants will be 19–69 years old, have had a confirmed or physician-suspected SARS-CoV-2 infection at least 3 months prior and meet clinical criteria for PCFS adapted from the Institute of Medicine ME/CFS criteria. Individuals who are taking opioid medications, have a history of ME/CFS prior to COVID-19 or history of significant liver disease will be excluded. Participants will be randomised to an LDN intervention arm (n=80) or placebo arm (n=80). Participants in each arm will be prescribed identical capsules starting at 1 mg daily and follow a prespecified schedule for up-titration to 4.5 mg daily or the maximum tolerated dose. The trial will be conducted over 16 weeks, with assessments at baseline, 6, 12 and 16 weeks. The primary outcome will be fatigue severity at 16 weeks evaluated by the Fatigue Severity Scale. Secondary outcomes will include pain Visual Analogue Scale score, overall symptom severity as measured by the Patient Phenotyping Questionnaire Short Form, 7-day step count and health-related quality of life measured by the EuroQol 5-Dimension questionnaire.Ethics and disseminationThe trial has been authorised by Health Canada and approved by The University of British Columbia/Children’s and Women’s Health Centre of British Columbia Research Ethics Board. On completion, findings will be disseminated to patients, caregivers and clinicians through engagement activities within existing PCC and ME/CFS networks. Results will be published in academic journals and presented at conferences.Trial registration numberNCT05430152.
Funder
BC Women’s Health Foundation
Canadian Institutes of Health Research
British Columbia Ministry of Health
BCCDC Foundation for Public Health
CAN-TAP-TALENT & Michael Smith Health Research BC
The University of British Columbia Clinician Investigator Program
St. Paul's Foundation
Reference126 articles.
1. Statistics Canada . Long-term symptoms in Canadian adults who tested positive for COVID-19 or suspected an infection, January 2020 to August 2022, 2022. Available: https://www150.statcan.gc.ca/n1/daily-quotidien/221017/dq221017b-eng.pdf [Accessed 24 Feb 2023].
2. National Center for Health Statistics . Long COVID household pulse survey. Available: www.cdc.gov/nchs/covid19/pulse/long-covid.htm [Accessed 1 Oct 2023].
3. Adjaye-Gbewonyo D , Vahratian A , Perrine CG , et al . Key findings Data from the National Health Interview Survey What percentage of adults ever had Long COVID or currently have Long COVID, and did it differ by sex?, Available: https://www.cdc.gov/nchs/products/index.htm
4. Recovery and symptom Trajectories up to two years after SARS-Cov-2 infection: population based, longitudinal cohort study;Ballouz;BMJ,2023
5. Long COVID: major findings, mechanisms and recommendations
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献